Chen Xinhua, Zhu Yu, Zhao Mingli, Hu Yanfeng, Luo Jun, Chen Yuehong, Lin Tian, Chen Hao, Liu Hao, Li Guoxin, Yu Jiang
Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
J Minim Access Surg. 2021 Jan-Mar;17(1):14-20. doi: 10.4103/jmas.JMAS_35_19.
The enhanced recovery after surgery (ERAS) programme is feasible and effective in reducing the length of hospital stay, overall complication rates and medical costs when applied to cases involving colonic and rectal resections. However, a recent prospective, randomised, open, parallel-controlled trial (Chinese Laparoscopic Gastrointestinal Surgery Study-01 trial), initiated by our team, indicated that under conventional peri-operative management, the reduction of the post-operative hospital stay of laparoscopic distal gastrectomy (LDG) is quite limited compared with open gastrectomy. Thus, if we could provide valuable clinical evidence for demonstrating the efficacy of the ERAS programme for gastric cancer patients undergoing LDG, it would significantly enhance the peri-operative management of gastrectomy and benefit the patients.
In this prospective single-arm trial, patients who are 18-75 years of age with gastric adenocarcinoma diagnosed with cT1-4aN0-3M0 and expected to undergo curative resection through LDG, are considered eligible for this study. All participants underwent LDG with peri-operative management under the ERAS programme. The primary outcome measures included the post-operative hospital stays and rehabilitative rate of the post-operative day 4. The secondary outcome measures are morbidity and mortality (time frame: 30 days), post-operative recovery index (time frame: 30 days), post-operative pain intensity (time frame: 3 days) and the medical costs from surgery to discharge.
With reasonable and scientific designing, the trial may be a great help to further discuss the benefit of ERAS programme and thus improving the peri-operative management of patients with gastrectomy.
手术加速康复(ERAS)方案应用于结肠和直肠切除病例时,在缩短住院时间、降低总体并发症发生率和医疗成本方面是可行且有效的。然而,我们团队发起的一项近期前瞻性、随机、开放、平行对照试验(中国腹腔镜胃肠手术研究 - 01试验)表明,在传统围手术期管理下,与开腹胃切除术相比,腹腔镜远端胃切除术(LDG)术后住院时间的缩短相当有限。因此,如果我们能够提供有价值的临床证据来证明ERAS方案对接受LDG的胃癌患者的疗效,将显著改善胃切除术的围手术期管理并使患者受益。
在这项前瞻性单臂试验中,年龄在18 - 75岁、诊断为cT1 - 4aN0 - 3M0的胃腺癌且预计通过LDG进行根治性切除的患者被认为符合本研究条件。所有参与者均在ERAS方案下接受LDG及围手术期管理。主要结局指标包括术后住院时间和术后第4天的康复率。次要结局指标为发病率和死亡率(时间范围:30天)、术后恢复指数(时间范围:30天)、术后疼痛强度(时间范围:3天)以及从手术到出院的医疗费用。(注:这里的“康复率”原文未明确说明具体定义,可能需要结合更多背景信息理解)
通过合理科学的设计,该试验可能有助于进一步探讨ERAS方案的益处,从而改善胃切除术患者的围手术期管理。